4D Molecular Therapeutics, Inc. cash flow to debt ratio of -509.42% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

4D Molecular Therapeutics, Inc.'s free cash flow has increased -21.17% from $-138.37M last year to $-109.08M, signaling increasing performance

4D Molecular Therapeutics, Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

4D Molecular Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.05 last year to 0.05 today, signaling weakened financials

4D Molecular Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

4D Molecular Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

4D Molecular Therapeutics, Inc.'s profit margin has increased (-99.96%) in the last year from -434.78K% to -182.34%, signaling increasing performance

4D Molecular Therapeutics, Inc.'s short-term assets of $413.13M exceed its short-term liabilities of $43.98M

4D Molecular Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

4D Molecular Therapeutics, Inc.'s return on equity of -36.83%, is lower than 15.00%, indicating bad performance

4D Molecular Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

4D Molecular Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

4D Molecular Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

4D Molecular Therapeutics, Inc. has negative free cash flow, indicating cash burn

4D Molecular Therapeutics, Inc.'s yearly earnings has increased -12.90% since last year from $-160.87M to $-140.11M, signaling increasing performance

4D Molecular Therapeutics, Inc.'s yearly revenue has increased 230.19K% since last year from $37.00K to $85.21M, signaling increasing performance

ROIC -37.80% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

4D Molecular Therapeutics, Inc.'s 3-year revenue CAGR of 200.86% is positive, indicating growing revenue over the past 3 years

4D Molecular Therapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

4D Molecular Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

4D Molecular Therapeutics, Inc. has insufficient data to evaluate this check.

4D Molecular Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

4D Molecular Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

4D Molecular Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

4D Molecular Therapeutics, Inc. has insufficient data to evaluate this check.

4D Molecular Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

4D Molecular Therapeutics, Inc. has a price-to-book ratio of 1.75x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

4D Molecular Therapeutics, Inc. has a price-to-sales ratio of 6.87x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue